Acer Therapeutics (NASDAQ: ACER)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | -0.640 | -0.2300 | ||||
REV | 2.500M | 0 | -2.500M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Acer Therapeutics (NASDAQ: ACER) through any online brokerage.
Other companies in Acer Therapeutics’s space includes: Cingulate (NASDAQ:CING), Graybug Vision (NASDAQ:GRAY), Onconova Therapeutics (NASDAQ:ONTX), Akanda (NASDAQ:AKAN) and Universe Pharmaceuticals (NASDAQ:UPC).
The latest price target for Acer Therapeutics (NASDAQ: ACER) was reported by EF Hutton on Wednesday, February 2, 2022. The analyst firm set a price target for 9.00 expecting ACER to rise to within 12 months (a possible 637.70% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Acer Therapeutics (NASDAQ: ACER) is $1.22 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Acer Therapeutics.
Acer Therapeutics’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Acer Therapeutics.
Acer Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.